Advertisement

Clinical Activity of Gemcitabine as a Single Agent and in Combination

  • Judith R. Kroep
  • Godefridus J. Peters
  • Robert A. Nagourney
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Gemcitabine (2′,2′-difluoro-deoxycytidine, dFdC, Gemzar®) is active in various solid tumors and hematological malignancies. It is attractive for combination chemotherapy based on its multiple mechanisms of action and relatively mild toxicity profile. This chapter summarizes the current preclinical and clinical knowledge of gemcitabine as a single agent and in combinations in non-small cell lung cancer, and pancreatic, bladder, breast, ovarian, gastric, and esophageal cancer.

Key Words

Breast cancer cisplatin gemcitabine gemcitabine combinations non-small cell lung cancer ovarian cancer pancreatic cancer radiotherapy taxanes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma. Br J Haematol 2001;113:772–778.PubMedGoogle Scholar
  2. 2.
    Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2′-deoxy-2′,2′-difluoroD-ribose and 2′-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988;53:2406–2409.Google Scholar
  3. 3.
    Braakhuis BJ, Ruiz Van Haperen V, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335–2340.PubMedGoogle Scholar
  4. 4.
    Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533–539.PubMedGoogle Scholar
  5. 5.
    Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024–4031.PubMedGoogle Scholar
  6. 6.
    Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417–4422.PubMedGoogle Scholar
  7. 7.
    Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110–6117.PubMedGoogle Scholar
  8. 8.
    Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996;14:243–247.PubMedGoogle Scholar
  9. 9.
    Gale RP. Advances in the treatment of acute myelogenous leukemia. N Engl J Med 1979;300:1189–1199.PubMedGoogle Scholar
  10. 10.
    Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia 1998;12(suppl 1):S16–S19.PubMedGoogle Scholar
  11. 11.
    Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447–453.PubMedGoogle Scholar
  12. 12.
    Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.PubMedGoogle Scholar
  13. 13.
    Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347–353.PubMedGoogle Scholar
  14. 14.
    Nagourney RA. Gemcitabine plus cisplatin in breast cancer. Oncology (Huntingt) 2001;15:28–33.Google Scholar
  15. 15.
    Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM. 2-Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993;67:10–14.PubMedGoogle Scholar
  16. 16.
    Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000;18:2245–2249.PubMedGoogle Scholar
  17. 17.
    Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88:35–39.PubMedGoogle Scholar
  18. 18.
    Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349–4357.PubMedGoogle Scholar
  19. 19.
    Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993;46:762–766.Google Scholar
  20. 20.
    Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994;48:1327–1339.Google Scholar
  21. 21.
    van Moorsel CJ, Bergman AM, Veerman G, et al. Differential effects of gemcitabine on ribonucleotide pools of 21 solid tumour and leukaemia cell lines. Biochim Biophys Acta 2000;1474:5–12.PubMedGoogle Scholar
  22. 22.
    Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000;87:227–253.PubMedGoogle Scholar
  23. 23.
    Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995;22:11–18.PubMedGoogle Scholar
  24. 24.
    Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997;94:1795–1799.PubMedGoogle Scholar
  25. 25.
    Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-smallcell lung cancer cell lines. Br J Cancer 2000;83:1069–1076.PubMedGoogle Scholar
  26. 26.
    Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999;35:796–807.PubMedGoogle Scholar
  27. 27.
    Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. LeukRes 1995;19:849–856.Google Scholar
  28. 28.
    Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181–188.PubMedGoogle Scholar
  29. 29.
    Ferreira CG, Tolis C, Span SW, et al. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000;6:203–212.PubMedGoogle Scholar
  30. 30.
    Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78–85.PubMedGoogle Scholar
  31. 31.
    Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999;59:4204–4207.PubMedGoogle Scholar
  32. 32.
    Ruiz van Haperen VWT, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994;54:4138–4143.Google Scholar
  33. 33.
    Al Madhoun AS, van der Wilt CL, Loves WJ, et al. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Biochem Pharmacol 2004;68:601–609.Google Scholar
  34. 34.
    Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002;1:371–376.PubMedGoogle Scholar
  35. 35.
    Spasokoukotskaja T, Arner ES, Brosjo O, et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995;31A:202–208.PubMedGoogle Scholar
  36. 36.
    Weber G, Singhal RL, Abonyi M, et al. Regulation of deoxycytidine kinase activity and inhibition by DFDC. Adv Enzyme Regul 1993;33:39–59.PubMedGoogle Scholar
  37. 37.
    Bergman AM, Giaccone G, van Moorsel CJ, et al. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 2000;36:1974–1983.PubMedGoogle Scholar
  38. 38.
    O’Rourke TJ, Brown TD, Havlin K, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on five consecutive days. Eur J Cancer 1994;30A:417, 418.PubMedGoogle Scholar
  39. 39.
    Vermorken JB, Guastalla JP, Hatty SR, et al. Phase I study of gemcitabine using a once every 2 wk schedule. Br J Cancer 1997;76:1489–1493.PubMedGoogle Scholar
  40. 40.
    Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs 1997;15:115–121.PubMedGoogle Scholar
  41. 41.
    Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821–1826.PubMedGoogle Scholar
  42. 42.
    Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992;10:406–413.PubMedGoogle Scholar
  43. 43.
    Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002;41:93–103.PubMedGoogle Scholar
  44. 44.
    Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: 30-min infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402–3408.PubMedGoogle Scholar
  45. 45.
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491–498.PubMedGoogle Scholar
  46. 46.
    Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of anti-metabolites. Cancer Surv 1993;17:123–156.PubMedGoogle Scholar
  47. 47.
    van Moorsel CJ, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999;10:441–448.PubMedGoogle Scholar
  48. 48.
    Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999;17:2190–2197.PubMedGoogle Scholar
  49. 49.
    Edzes HT, Peters GJ, Noordhuis P, Vermorken JB. Determination of the antimetabolite gemcitabine (2′,2′-difluoro-2′-deoxycytidine) and of 2′,2′-difluoro-2′-deoxyuridine by 19F nuclear magnetic resonance spectroscopy. Anal Biochem 1993;214:25–30.PubMedGoogle Scholar
  50. 50.
    Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258–262.PubMedGoogle Scholar
  51. 51.
    Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24:S7.PubMedGoogle Scholar
  52. 52.
    Martin C, Pollera CF. Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res 1996;16:9–18.PubMedGoogle Scholar
  53. 53.
    Gemcitabine US prescribing information. Eli Lilly and Company;2002. Internet communication, http://www.gemzar.com/hcp/for-oncology-professionals.jsp.
  54. 54.
    Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002;20:311–315.PubMedGoogle Scholar
  55. 55.
    Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002;40:E16.PubMedGoogle Scholar
  56. 56.
    Voorburg AM, van Beek FT, Slee PH, Seldenrijk CA, Schramel FM. Vasculitis due to gemcitabine. Lung Cancer 2002;36:203–205.PubMedGoogle Scholar
  57. 57.
    Chou TC, Talalay P. Application of the median-effect principle for the assessment of low risk carcinogens and for quantitation of synergism and antagonism of chemotherapeutic agents. In: Harrap KR, Connors TA, eds. New Avenues in Developmental Cancer Chemotherapy. New York: Academic Press,1987:37–64.Google Scholar
  58. 58.
    Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug interactions with DNA. ChemRev 1987;87:1153–1181.Google Scholar
  59. 59.
    Bergman AM, Ruiz Van Haperen V, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521–530.PubMedGoogle Scholar
  60. 60.
    van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981–990.PubMedGoogle Scholar
  61. 61.
    van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 1999;35:808–814.PubMedGoogle Scholar
  62. 62.
    Kroep JR, Peters GJ, van Moorsel CJ, et al. Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 1999;10:1503–1510.PubMedGoogle Scholar
  63. 63.
    Abratt RP, Sandler A, Crino L, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 1998;25:35–43.PubMedGoogle Scholar
  64. 64.
    Ricci S, Antonuzzo A, Galli L, et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer 2000;89:1714–1719.PubMedGoogle Scholar
  65. 65.
    Soto PH, Cavina R, Latteri F, et al. Three-wk vs 4-wk schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002;13:1080–1086.Google Scholar
  66. 66.
    Theodossiou C, Cook JA, Fisher J, et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998;12:825–832.PubMedGoogle Scholar
  67. 67.
    Shewach DS, Reynolds KK, Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 1992;42:518–524.PubMedGoogle Scholar
  68. 68.
    Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM, Peters G. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1996;51:911–918.Google Scholar
  69. 69.
    Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117–123.PubMedGoogle Scholar
  70. 70.
    Zoli W, Ricotti L, Dal Susino M, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 1999;81:609–615.PubMedGoogle Scholar
  71. 71.
    van Moorsel CJ, Pinedo HM, Veerman G, et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 1999;57:407–415.PubMedGoogle Scholar
  72. 72.
    Aung TT, Davis MA, Ensminger WD, Lawrence TS. Interaction between gemcitabine and mitomycin-C in vitro. Cancer Chemother Pharmacol 2000;45:38–42.PubMedGoogle Scholar
  73. 73.
    Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000;60:6075–6079.PubMedGoogle Scholar
  74. 74.
    Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671–3676.PubMedGoogle Scholar
  75. 75.
    Csapo Z, Keszler G, Sasvari-Szekely M, et al. Similar changes were induced by cladribine and by gemcitabine, in the deoxypyrimidine salvage, during shortterm treatments. Adv Exp Med Biol 1998;431:525–529.PubMedGoogle Scholar
  76. 76.
    Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218–3223.PubMedGoogle Scholar
  77. 77.
    van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga HH. End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 2001;61:1585–1591.PubMedGoogle Scholar
  78. 78.
    McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88:1193–1203.PubMedGoogle Scholar
  79. 79.
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899–909.Google Scholar
  80. 80.
    Carney DN, Hansen HH. Non-small-cell lung cancer—stalemate or progress? N Engl J Med 2000;343:1261–1262.PubMedGoogle Scholar
  81. 81.
    Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care vs supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074–1080.PubMedGoogle Scholar
  82. 82.
    Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care vs best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145–157.PubMedGoogle Scholar
  83. 83.
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66–72.Google Scholar
  84. 84.
    Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 2004;58:991–1002.PubMedGoogle Scholar
  85. 85.
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 1. J Clin Oncol 2004;22:777–784.PubMedGoogle Scholar
  86. 86.
    Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI 774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;617.Google Scholar
  87. 87.
    Ng EW, Sandler AB, Robinson L, Einhorn LH. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group study. Am J Clin Oncol 1999;22:550–553.PubMedGoogle Scholar
  88. 88.
    Page JD, Husain I, Sancar A, Chaney SG. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990;29:1016–1024.PubMedGoogle Scholar
  89. 89.
    Giaccone G, Smit EF, van Meerbeeck JP, et al. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 2000;11:109–112.PubMedGoogle Scholar
  90. 90.
    Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 1999;17:914–920.PubMedGoogle Scholar
  91. 91.
    Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin vs gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578–3585.PubMedGoogle Scholar
  92. 92.
    Douillard JY, Lerouge D, Monnier A, et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 2001;84:1179–1184.PubMedGoogle Scholar
  93. 93.
    Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001;19:1071–1077.PubMedGoogle Scholar
  94. 94.
    Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-smallcell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909–3917.PubMedGoogle Scholar
  95. 95.
    Klein B, Sadikov E, Mishaeli M, Levin I, Figer A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol Rep 2000;7:875–877.PubMedGoogle Scholar
  96. 96.
    Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261–1268.PubMedGoogle Scholar
  97. 97.
    Brodowicz T, Wolfram RM, Kostler WJ, et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 2000;11:623–628.PubMedGoogle Scholar
  98. 98.
    Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000;11:1399–1403.PubMedGoogle Scholar
  99. 99.
    Smid K, van Moorsel CJ, Noordhuis P, Voorn DA, Peters GJ. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int J Oncol 2001;19:157–162.PubMedGoogle Scholar
  100. 100.
    Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 2000;58:215–218.PubMedGoogle Scholar
  101. 101.
    Cascinu S, Silva RR, Barni S, et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999;80:1595–1598.PubMedGoogle Scholar
  102. 102.
    Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585–592.PubMedGoogle Scholar
  103. 103.
    Rauch DP, Maurer CA, Aebi S, et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 2001;60:43–48.PubMedGoogle Scholar
  104. 104.
    Kurtz JE, Kohser F, Negrier S, et al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterology 2000;47:1450–1453.PubMedGoogle Scholar
  105. 105.
    Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III. Phase III study of gemcitabine in combination with fluorouracil vs gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270–3275.PubMedGoogle Scholar
  106. 106.
    Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999;10:1377–1379.PubMedGoogle Scholar
  107. 107.
    Ryan DP, Kulke MH, Fuchs CS, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002;94:97–103.PubMedGoogle Scholar
  108. 108.
    Fine RL, Fogelman DR, Schreibman S. GTX chemotherapy for metastatic pancreatic cancer: response, survival and toxicity data. Proc Am Soc Clin Oncol 2004:23(abstr. 4271).Google Scholar
  109. 109.
    Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246–2253.PubMedGoogle Scholar
  110. 110.
    Pipas JM, Mitchell SE, Barth RJ Jr, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001;50:1317–1322.PubMedGoogle Scholar
  111. 111.
    de Lange SM, van Groeningen CJ, Meijer OW, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212–1217.PubMedGoogle Scholar
  112. 112.
    McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202–4208.PubMedGoogle Scholar
  113. 113.
    Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3:1463–1470.PubMedGoogle Scholar
  114. 114.
    Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–1073.PubMedGoogle Scholar
  115. 115.
    Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050–1055.PubMedGoogle Scholar
  116. 116.
    von der Maasse H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999;10:1461–1465.Google Scholar
  117. 117.
    Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.PubMedGoogle Scholar
  118. 118.
    Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:2876–2881.PubMedGoogle Scholar
  119. 119.
    von der Maasse H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin vs methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase m study. J Clin Oncol 2000;18:3068–3077.Google Scholar
  120. 120.
    Meluch AA, Greco FA, Burris HA III, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19:3018–3024.PubMedGoogle Scholar
  121. 121.
    Fuchs CS. Chemotherapy for advanced gastric cancer: where do we stand? J Clin Oncol 1997;15:3299–3300.PubMedGoogle Scholar
  122. 122.
    Leichman L, Berry BT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol 1991;18:64–72.PubMedGoogle Scholar
  123. 123.
    Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 1991;18:25–33.PubMedGoogle Scholar
  124. 124.
    Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261–267.PubMedGoogle Scholar
  125. 125.
    Kulke MH. The treatment of advanced gastric cancer: in search of the right combination. J Clin Oncol 2000;18:2645–2647.PubMedGoogle Scholar
  126. 126.
    Sandler AB, Kindler HL, Einhorn LH, et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 2000;11:1161–1164.PubMedGoogle Scholar
  127. 127.
    de Lange SM, van Groeningen CJ, Kroep JR, et al. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 2004;15:484–488.PubMedGoogle Scholar
  128. 128.
    Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, van Groeningen CJ. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 2004;15:230–235.PubMedGoogle Scholar
  129. 129.
    Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002;62:2–8.PubMedGoogle Scholar
  130. 130.
    Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731–2736.PubMedGoogle Scholar
  131. 131.
    Possinger K, Kaufmann M, Coleman R, et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155–162.PubMedGoogle Scholar
  132. 132.
    Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303–307.PubMedGoogle Scholar
  133. 133.
    Akrivakis K, Schmid P, Flath B, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999;10:525–531.PubMedGoogle Scholar
  134. 134.
    Donadio M, Ardine M, Berruti A, et al. Gemcitabine and vinorelbine as secondline treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 2003;52:147–152.PubMedGoogle Scholar
  135. 135.
    Lobo F, Virizuela JA, Dorta FJ, et al. Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 2003;4:46–50.PubMedGoogle Scholar
  136. 136.
    Nicolaides C, Dimopoulos MA, Samantas E, et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2000;11:873–875.PubMedGoogle Scholar
  137. 137.
    Sanal SM, Gokmen E, Karabulut B, Sezgin C. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 2002;8:171–176.PubMedGoogle Scholar
  138. 138.
    Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 2002;20:37–41.PubMedGoogle Scholar
  139. 139.
    Zielinski CC. Gemcitabine/anthracycline combinations in metastatic breast cancer. Clin Breast Cancer 2002;3(suppl 1):30–33.PubMedGoogle Scholar
  140. 140.
    Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3249–3254.PubMedGoogle Scholar
  141. 141.
    Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004;15:201–206.PubMedGoogle Scholar
  142. 142.
    Colomer R, Llombart A, Lluch A, et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000;27:20–24.PubMedGoogle Scholar
  143. 143.
    Delfino C, Caccia G, Riva GL, et al. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer. Oncology (Huntingt) 2003;17:22–25.Google Scholar
  144. 144.
    Murad AM, Guimaraes RC, Aragao BC, Scalabrini-Neto AO, Rodrigues VH, Garcia R. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol 2001;24:264–268.PubMedGoogle Scholar
  145. 145.
    Alexopoulos A, Tryfonopoulos D, Karamouzis MV, et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 2004;15:95–99.PubMedGoogle Scholar
  146. 146.
    Brandi M, Vici P, Lopez M, et al. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 2004;31:13–19.PubMedGoogle Scholar
  147. 147.
    Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 2000;18:503–509.PubMedGoogle Scholar
  148. 148.
    Laufman LR, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 2001;12:1259–1264.PubMedGoogle Scholar
  149. 149.
    O’Shaughnessy J, Nag S, Caldirello Riuz J. Gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as first line treatment for anthracycline pretreated metastatic breast cancer (MBC): Interim results of a global phase II study. Proc Am Soc Clin Oncol 2003;22:7(abstr. 25).Google Scholar
  150. 150.
    Musib L, Cleverly AL, Roychowdhury DF. Gemcitabine (G) and paclitaxel (T) pharmacokinetics (PK): lack of an interaction in a D1 (T-G), d 8 G, every 21 d schedule. Proc Am Soc Clin Oncol 2003;22:0161(abstr. 644).Google Scholar
  151. 151.
    Zielinski CC. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Huntingt) 2003;17:36–40.Google Scholar
  152. 152.
    Nasr FL, Chahine GY, Kattan JG, et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 2004;5:117–122.PubMedGoogle Scholar
  153. 153.
    O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5:142–147.PubMedGoogle Scholar
  154. 154.
    Sledge GW Jr. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2003;17:33–35.Google Scholar
  155. 155.
    Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343–1345.PubMedGoogle Scholar
  156. 156.
    Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530–1533.PubMedGoogle Scholar
  157. 157.
    Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89–93.PubMedGoogle Scholar
  158. 158.
    Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 1999;22:450–452.PubMedGoogle Scholar
  159. 159.
    von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853–855.Google Scholar
  160. 160.
    D′Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266–269.PubMedGoogle Scholar
  161. 161.
    Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003;90:593–596.PubMedGoogle Scholar
  162. 162.
    Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003;88:1963–1970.PubMedGoogle Scholar
  163. 163.
    Garcia AA, O’Meara A, Bahador A, et al. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004;93:493–498.PubMedGoogle Scholar
  164. 164.
    Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. Onkologie 2004;27:58–64.PubMedGoogle Scholar
  165. 165.
    Goff BA, Thompson T, Greer BE, Jacobs A, Storer B. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: a phase WI trial of the Puget Sound Oncology Consortium (PSOC 1602). Am J Obstet Gynecol 2003;188:1556–1562.PubMedGoogle Scholar
  166. 166.
    Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrugresistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003;88:17–21.PubMedGoogle Scholar
  167. 167.
    Nogue M, Cirera L, Arcusa A, et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 2002;13:839–845.PubMedGoogle Scholar
  168. 168.
    Bauknecht T, Hefti A, Morack G, et al. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003;13:130–137.PubMedGoogle Scholar
  169. 169.
    Belpomme D, Krakowski I, Beauduin M, et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecol Oncol 2003;91:32–38.PubMedGoogle Scholar
  170. 170.
    Du Bois BA, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001;12:1115–1120.PubMedGoogle Scholar
  171. 171.
    Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol 2004;92:152–159.PubMedGoogle Scholar
  172. 172.
    Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:93–100.PubMedGoogle Scholar
  173. 173.
    Micha JP, Goldstein BH, Rettenmaier MA, et al. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 2004;94:719–724.PubMedGoogle Scholar
  174. 174.
    Liu FS, Ho ES, Hung MJ, Hwang SF, Lu CH, Ke YM. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. Gynecol Oncol 2004;94:393–397.PubMedGoogle Scholar
  175. 175.
    Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 2003;90:S1–S7.PubMedGoogle Scholar
  176. 176.
    Gebbia V, Testa A, Borsellino N, et al. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999;150:11–15.PubMedGoogle Scholar
  177. 177.
    Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998;34:1208–1212.PubMedGoogle Scholar
  178. 178.
    Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441–3445.PubMedGoogle Scholar
  179. 179.
    Stadler VM, Murphy B, Kaufman D. Phase II trial of gemcitabine plus cisplatin in metastatic urothelial cancer. Proc Am Soc Clin Oncol 16,323. 1997.Google Scholar
  180. 180.
    Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999;10:625–631.PubMedGoogle Scholar
  181. 181.
    Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994;73:5–7.PubMedGoogle Scholar
  182. 182.
    Sessa C, Aamdal S, Wolff I, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:471–472.PubMedGoogle Scholar
  183. 183.
    Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999;17:509–511.PubMedGoogle Scholar
  184. 184.
    Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001;31:277–284.PubMedGoogle Scholar
  185. 185.
    Perng RP, Chen YM, Ming-Liu J, et al. Gemcitabine vs the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097–2102.PubMedGoogle Scholar
  186. 186.
    Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:283–285.PubMedGoogle Scholar
  187. 187.
    De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996;37:491–495.PubMedGoogle Scholar
  188. 188.
    Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993;4:331–332.PubMedGoogle Scholar
  189. 189.
    Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:543–547.PubMedGoogle Scholar
  190. 190.
    Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101–105.PubMedGoogle Scholar
  191. 191.
    Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29–34.PubMedGoogle Scholar
  192. 192.
    Ulrich-Pur H, Kornek GV, Raderer M, et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 2000;88:2505–2511.PubMedGoogle Scholar
  193. 193.
    Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin vs etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12–18.PubMedGoogle Scholar
  194. 194.
    Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin vs mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522–3530.PubMedGoogle Scholar
  195. 195.
    Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin vs cisplatin alone in patients with locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2000;18:122–130.PubMedGoogle Scholar
  196. 196.
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine vs vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529–2536.PubMedGoogle Scholar
  197. 197.
    Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.PubMedGoogle Scholar
  198. 198.
    Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) vs cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 2002;37:9–14.PubMedGoogle Scholar
  199. 199.
    Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451–1457.PubMedGoogle Scholar
  200. 200.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.PubMedGoogle Scholar
  201. 201.
    Sculier JP, Lafitte JJ, Lecomte J, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002;13:874–882.PubMedGoogle Scholar
  202. 202.
    Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gyn Oncol 2006; in press.Google Scholar
  203. 203.
    Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gyn Oncol 2006;100:385–388.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Judith R. Kroep
    • 1
  • Godefridus J. Peters
    • 1
  • Robert A. Nagourney
    • 2
  1. 1.Department Medical OncologyVU University Medical CenterAmsterdamThe Netherlands
  2. 2.Rational Therapeutics Inc.Malcolm C. Todd Cancer InstituteLong Beach

Personalised recommendations